Article
Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state
2024-11-12
Abstract excerpt
<h4>ABSTRACT</h4> The discovery of oncogene addiction in cancer has led to the development of over a dozen FDA-approved biomarker-driven therapies in lung adenocarcinoma. Somatic mutations of the “Ras-like in all tissues” (RIT1) gene are non-canonical driver events in lung cancer, occurring in ∼2% of lung adenocarcinomas in a mutually exclusive fashion with KRAS and EGFR mutations. Patients with RIT1 -mutant l...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 261219e9-e3d3-5cb2-b6fe-13e7b96b1527
- DOI
- 10.1101/2024.11.11.623044
